Physical, but not laboratory, treatment‐related adverse events are associated with favorable outcomes of enfortumab vedotin for advanced urothelial carcinoma: A landmark analysis
Körperliche, aber nicht laborbezogene, behandlungsbedingte unerwünschte Ereignisse sind mit günstigen Ergebnissen von Enfortumab Vedotin bei fortgeschrittenem Urothelkarzinom assoziiert: Landmark-Analyse
International Journal of Urology · 2025-03 · 32 (3) · 270-276
DOI: 10.1111/iju.15640 ↗Auf einen Blick
Bei 106 Patient:innen mit fortgeschrittenem Urothelkarzinom war Enfortumab Vedotin häufig mit trAEs verbunden. In der Landmark-Analyse waren körperliche, nicht aber laborbezogene trAEs mit längerem Überleben assoziiert.
Fragestellung
Welche prognostische Bedeutung haben behandlungsbedingte unerwünschte Ereignisse unter Enfortumab Vedotin bei fortgeschrittenem Urothelkarzinom?
Methode
Rückblickende Analyse von 106 Patient:innen aus 10 Zentren (2021–2023); Cox-Modelle für OS und PFS; Landmark-Analyse zu trAEs zur Minimierung von immortal time bias.
Ergebnisse
Von 106 Patient:innen hatten 94 (88,7 %) trAEs jeder Schwere und 44 (41,5 %) trAEs ≥ Grad 3. Unter 88 Patient:innen mit ≥ 2 Monaten Überleben waren trAEs signifikant mit längerer Überlebenszeit assoziiert.
Schlussfolgerung der Autor:innen
Körperliche, aber nicht laborbezogene trAEs sind mit günstigen Ergebnissen der EV-Therapie bei fortgeschrittenem Urothelkarzinom assoziiert.
Kernaussagen
- trAEs traten bei 88,7 % der Patient:innen auf
- Landmark-Analyse: trAEs mit längerem Überleben assoziiert
- Körperliche trAEs günstig, laborbezogene trAEs ungünstig assoziiert
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Multizentrische Studie in der Zeitschrift International Journal of Urology, online erschienen am 22.11.2024. Verfasst von Satoru Taguchi und 37 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Themen: Patientensicherheit
Abstract (Originalsprache)
Background
While the occurrence of immune‐related adverse events has been recognized as a prognostic marker in patients receiving immune checkpoint inhibitors, the prognostic significance of treatment‐related adverse events (trAEs) in patients undergoing antibody–drug conjugates such as enfortumab vedotin (EV) is controversial.
Methods
We reviewed 106 patients with advanced urothelial carcinoma who were treated with EV therapy at 10 institutions between 2021 and 2023. Associations of clinical parameters with overall survival and progression‐free survival were assessed using the Cox proportional hazards model. For the assessment of trAEs, landmark analysis was conducted to minimize immortal time bias.
Results
Of 106 patients, 55 (51.9%) experienced disease progression and 44 (41.5%) died during the follow‐up period. Any grade and grade ≥3 trAEs occurred in 94 (88.7%) and 44 (41.5%) patients, respectively. Common trAEs included skin disorders (74.5%), gastrointestinal disorders (62.3%), fatigue (50.0%), peripheral neuropathy (36.8%), and hematological disorders (37.7%). One patient died of interstitial pneumonia (grade 5). According to landmark analysis using 88 patients who survived for 2 months or more, trAEs were significantly associated with longer survival. Furthermore, when trAEs were classified into “physical trAEs” such as skin disorders and “laboratory trAEs” such as hematological disorders, the former were associated with longer survival while the latter were associated with shorter survival.
Conclusions
Physical, but not laboratory, trAEs are associated with favorable outcomes of EV therapy for advanced urothelial carcinoma. Both managing trAEs and utilizing them as prognostic markers are key points in the use of antibody–drug conjugates such as EV.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan.
- Department of Urology, International University of Health and Welfare Ichikawa Hospital, Ichikawa, Chiba, Japan.
- Department of Urology, Teikyo University School of Medicine, Itabashi-ku, Tokyo, Japan.
- Department of Urology, Kyorin University School of Medicine, Mitaka, Tokyo, Japan.
- Department of Urology, Jichi Medical University, Shimotsuke, Tochigi, Japan.
- Department of Urology, Nihon University School of Medicine, Itabashi-ku, Tokyo, Japan.
ORCID-Profile: Satoru Taguchi, Taketo Kawai, Tomoyuki Kaneko, Hayato Hoshina, Daisuke Obinata, Kenya Yamaguchi, Yuta Yamada, Aya Niimi, Tetsuya Fujimura, Satoru Takahashi
Zitieren
APA
Taguchi, S., Kawai, T., Ambe, Y., Kishitani, K., Noda, M., Kaneko, T., Miyakawa, J., Nakamura, Y., Hoshina, H., Obinata, D., Yamaguchi, K., Kakutani, S., Furuya, Y., Sato, Y., Adachi, Y., Sugimoto, K., Sato, K., Tabata, M., Tanaka, T., …, & Kume, H. (2025). Physical, but not laboratory, treatment‐related adverse events are associated with favorable outcomes of enfortumab vedotin for advanced urothelial carcinoma: A landmark analysis. International Journal of Urology, 32(3), 270-276. https://doi.org/10.1111/iju.15640
Vancouver
Taguchi S, Kawai T, Ambe Y, Kishitani K, Noda M, Kaneko T, et al. Physical, but not laboratory, treatment‐related adverse events are associated with favorable outcomes of enfortumab vedotin for advanced urothelial carcinoma: A landmark analysis. International Journal of Urology. 2025;32(3):270-276. doi:10.1111/iju.15640
BibTeX
@article{Taguchi2025,
author = {Taguchi, Satoru and Kawai, Taketo and Ambe, Yoshiki and Kishitani, Kenjiro and Noda, Michio and Kaneko, Tomoyuki and Miyakawa, Jimpei and Nakamura, Yu and Hoshina, Hayato and Obinata, Daisuke and Yamaguchi, Kenya and Kakutani, Shigenori and Furuya, Yoshitsune and Sato, Yujiro and Adachi, Yume and Sugimoto, Kazuma and Sato, Keigo and Tabata, Mariko and Tanaka, Takehiro and Nara, Katsuhiko and Uemura, Yukari and Kamei, Jun and Akiyama, Yoshiyuki and Sato, Yusuke and Yamada, Yuta and Niimi, Aya and Yamada, Daisuke and Takada, Tappei and Takahashi, Sayuri and Yamada, Yukio and Miyazaki, Hideyo and Enomoto, Yutaka and Nishimatsu, Hiroaki and Fujimura, Tetsuya and Fukuhara, Hiroshi and Nakagawa, Tohru and Takahashi, Satoru and Kume, Haruki},
title = {Physical, but not laboratory, treatment‐related adverse events are associated with favorable outcomes of enfortumab vedotin for advanced urothelial carcinoma: A landmark analysis},
journal = {International Journal of Urology},
year = {2025},
volume = {32},
number = {3},
pages = {270--276},
doi = {10.1111/iju.15640}
}
EUVIMED